Celgene to pay about $1 billion in cash and stock for Juno Therapeutics collaboration
June 30, 2015 at 09:44 AM EDT
Shares of Juno Therapeutics soared Tuesday morning, a day after larger drug developer Celgene announced plans to invest about $1 billion in Juno mostly through stock purchases as part of a collaboration to develop cancer and autoimmune disease treatments.
